Wipeout: Roche's anti-amyloid attack on presymptomatic Alzheimer's ends in failure

Roche’s long-running attempt to show its anti-amyloid-beta antibody works very early in the Alzheimer’s disease pathway has ended in defeat. The AC Immune-discovered candidate failed to improve outcomes in cognitively unimpaired individuals at high imminent risk for developing Alzheimer’s symptoms.